Saygun, OnurEyigün, Can PolatAvcı, İsmail YaşarKısa, ÜçlerPahsa, Alaaddin2021-01-142021-01-142009Saygun O., Eyigün C. P., Avcı İ. Y., Kısa Ü., Pahsa A. (2009). Investigation (in vivo and in vitro) of booster dose vaccine requirement for long-term protection against hepatitis b virus infection. Turkish Journal of Medical Sciences, 39(2), 173 - 177.1300-01441303-6165https://app.trdizin.gov.tr/makale/T1RBek56QXchttps://hdl.handle.net/20.500.12587/13144Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated. Materials and Methods: Seventeen individuals vaccinated previously were enrolled in the study. They had once developed a protective level of anti-HBs antibody after immunization and their anti-HBs titer had declined to an underprotective level. Twenty uninfected and unvaccinated healthy people were chosen as controls. Lymphoproliferative response to in-vitro stimulation with hepatitis B surface antigen (HBsAg) and anti-HBs response to vaccine were evaluated for immune response. Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg stimulation while none of the controls did (P < 0.05). In all subjects in the study group, anti-HBs response (?10 mIU/ml) was detected 1 to 7 days after the booster injection but in only 2 of the controls antibody response was detected 28 days after the first dose of HBV vaccine (P < 0.0001). Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated. Materials and Methods: Seventeen individuals vaccinated previously were enrolled in the study. They had once developed a protective level of anti-HBs antibody after immunization and their anti-HBs titer had declined to an underprotective level. Twenty uninfected and unvaccinated healthy people were chosen as controls. Lymphoproliferative response to in-vitro stimulation with hepatitis B surface antigen (HBsAg) and anti-HBs response to vaccine were evaluated for immune response. Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg stimulation while none of the controls did (P &lt; 0.05). In all subjects in the study group, anti-HBs response (&amp;#8805;10 mIU/ml) was detected 1 to 7 days after the booster injection but in only 2 of the controls antibody response was detected 28 days after the first dose of HBV vaccine (P &lt; 0.0001). Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.eninfo:eu-repo/semantics/openAccessCerrahiArticle3921731772-s2.0-65249168122Q190370WOS:000265263900003Q4